Effects of Different Doses of Rosuvastatin on Serum Levels of sOX40L and MMP-9 in Patients with Acute Coronary Syndrome
10.3969/j.issn.0253-9896.2014.09.025
- VernacularTitle:不同剂量瑞舒伐他汀对急性冠脉综合征患者血清sOX40L、MMP-9的影响
- Author:
Linjun WANG
- Publication Type:Journal Article
- Keywords:
rosuvastatin;
coronary artery disease;
matrix metalloproteinase 9;
soluble OX40 ligand
- From:
Tianjin Medical Journal
2014;(9):937-939
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore effects of different doses of rosuvastatin on serum soluble OX40 ligand (sOX40L), matrix metalloproteinase-9 (MMP-9) in patients with acute coronary syndrome (ACS). Methods Sixty patients with ACS were evenly divided into 20 mg rosuvastatin treatment group (20 mg group) and 10 mg rosuvastatin treatment group (10 mg group). Twenty healthy volunteers were randomly assigned to control group. The serum levels of sOX40L and MMP-9 were measured and analyzed before and after treatment in three groups. Results The levels of sOX40L and MMP-9 before treat-ment were significantly higher in two treatment groups than those in control group (P<0.01). After two-week treatment with rosuvastatin, serum levels of sOX40L and MMP-9 decreased significantly in two treatment groups compared with those of pre-treatment (P<0.01). Moreover, the levels of sOX40L and MMP-9 were significantly lower in 20 mg group than those in 10 mg group after two-week treatment with rosuvastatin (P<0.05). But the levels of sOX40L and MMP-9 were still higher than control group (P<0.01). Conclusion Larger doses of rosuvastatin may decrease the degradation of extraceller matrix of coronary atherosclerotic plaque and inflammatory reaction, stabilize coronary atherosclerotic vulnerable plaque, and play an important role in improving prognosis in patients with ACS.
